Question 1

What is Metastatic Colorectal Cancer?

Accepted Answer

Colorectal cancer (CRC) is the third most common, with metastasis being the major cause of death in the majority of patients. Common sites of distant metastasis are the liver and the peritoneum. CRC starts in the colon or the rectum. These cancers can also be called colon cancer or rectal cancer, depending on where they start. Colon cancer and rectal cancer are often grouped because they have many features in common. CRC may develop when polyps, mushroom-like growths inside the colon, grow and become cancerous or cells along the lining of the colon or rectum mutate and grow out of control, forming a tumor. CRC that spreads, or metastasizes, to the lungs, liver or any other organ is called metastatic colorectal cancer (mCRC). The most common site of metastasis for colon or rectal cancer is the liver. CRC cells may also spread to the lungs, bones, brain, or spinal cord. Approximately one-fifth of CRC cases are metastatic at the time of diagnosis. If a person has been treated for CRC and cancer cells have been found in these areas, it may be a sign that the original CRC has spread. mCRC is different from recurrent CRC. Most CRCs start as a growth on the inner lining of the colon or rectum. These growths are called polyps. Some types of polyps can change into cancer over time (usually many years), but not all polyps become cancer. The chance of a polyp turning into cancer depends on the type of polyp it is. There are different types of polyps.

Question 2

How is Metastatic Colorectal Cancer epidemiology segmented?

Accepted Answer

Metastatic Colorectal Cancer epidemiology is segmented as Metastatic Colorectal Cancer Total Incident Cases, Age-specific Metastatic Colorectal Cancer cases, Gender-specific Metastatic Colorectal Cancer Cases, Stage-specific Metastatic Colorectal Cancer incident cases, Type-specific Metastatic Colorectal Cancer incident cases, and Total Treated Metastatic Colorectal Cancer Cases.

Question 3

What is the Metastatic Colorectal Cancer market size in 7MM?

Accepted Answer

The Metastatic Colorectal Cancer market size is expected to grow owing to the launch of emerging therapies by 2032.

Question 4

At what CAGR is the Metastatic Colorectal Cancer Market expected to grow by 2032?

Accepted Answer

The Metastatic Colorectal Cancer Market is expected to grow at a moderate CAGR during the study period 2019–2032.

Question 5

Which country is expected to account for the most significant Metastatic Colorectal Cancer prevalent cases in the 7MM?

Accepted Answer

The United States is expected to account for the highest prevalent Metastatic Colorectal Cancer prevalent cases.

Question 6

What are the key Metastatic Colorectal Cancer companies?

Accepted Answer

Some of the key Metastatic Colorectal Cancer companies working in the Metastatic Colorectal Cancer market are Pfizer, Sanofi, Taiho Pharma, Ono Pharma, Hutchison Medipharma, Isofol Medical, Sumitomo Dainippon Pharma, G1 Therapeutics, Merck, AB Science, Pfizer, Daiichi Sankyo/Astrazeneca, Merck/Eisai, Mirati Therapeutics, Merck, Cardiff Oncology, and others.